Ajit P Limaye

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4957588/publications.pdf

Version: 2024-02-01

109	6,424	38	78
papers	citations	h-index	g-index
110	110	110	5986
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19. Clinical Infectious Diseases, 2024, 78, 711-718.	5.8	6
2	Unexpected Cytomegalovirus (CMV) Replication Kinetics in CMV Donor-Seropositive, Recipient-Seronegative Liver Transplant Recipients Receiving Preemptive Antiviral Therapy. Journal of Infectious Diseases, 2022, 225, 436-442.	4.0	6
3	Apples to Apples: The Challenges of Studying COVIDâ€19 Mortality in Solid Organ Transplant Recipients. American Journal of Transplantation, 2022, , .	4.7	2
4	Misplaced emphasis, misunderstood risk: a cultural history of Public Health Service infectious disease guidelines. Current Opinion in Organ Transplantation, 2022, 27, 159-164.	1.6	2
5	Vaccination, Transplantation, and a Social Contract. Journal of the American Society of Nephrology: JASN, 2022, 33, 1445-1447.	6.1	2
6	Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study. Clinical Infectious Diseases, 2021, 73, e4090-e4099.	5.8	332
7	Cost-effectiveness of Preemptive Therapy Versus Prophylaxis in a Randomized Clinical Trial for the Prevention of Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors. Clinical Infectious Diseases, 2021, 73, e2739-e2745.	5.8	15
8	COVID-19â€"Lessons Learned and Questions Remaining. Clinical Infectious Diseases, 2021, 72, 2225-2240.	5.8	54
9	Risk Factors for Cytomegalovirus Reactivation and Association With Outcomes in Critically Ill Adults With Sepsis: A Pooled Analysis of Prospective Studies. Journal of Infectious Diseases, 2021, 223, 2108-2112.	4.0	11
10	Risk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy. Journal of Infectious Diseases, 2021, 223, 1073-1077.	4.0	3
11	Disseminated Mycobacterium haemophilum With Tenosynovitis in a Liver Transplant Recipient. Journal of Clinical Rheumatology, 2021, 27, e36-e37.	0.9	3
12	Examining valganciclovir prophylaxis duration among highâ€risk donor seropositive/recipient seronegative heart transplant recipients in a larger cohort. Transplant Infectious Disease, 2021, 23, e13581.	1.7	1
13	SARS-CoV-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know?. Journal of the American Society of Nephrology: JASN, 2021, 32, 1021-1024.	6.1	28
14	Tacrolimus: Unlikely Harmful and Perhaps Helpful in Liver Transplant Recipients with COVID-19. Gastroenterology, 2021, 160, 1012-1013.	1.3	6
15	In with the new and, mostly better: Considering the OPTN bloodâ€borne virus policy updates. American Journal of Transplantation, 2021, 21, 3494-3495.	4.7	O
16	Immunosuppression in solid organ transplant recipients with Covidâ€19: More data, but still complicated. Transplant Infectious Disease, 2021, 23, e13650.	1.7	2
17	Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients. Liver Transplantation, 2021, 27, 1302-1311.	2.4	8
18	Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients. Transplant Infectious Disease, 2021, 23, e13687.	1.7	34

#	Article	IF	CITATIONS
19	Multiple liver lesions in a lung transplant recipient. American Journal of Transplantation, 2021, 21, 3801-3803.	4.7	O
20	Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients. Transplantation Direct, 2021, 7, e637.	1.6	0
21	Reply to Hage and Schuurmans. Clinical Infectious Diseases, 2021, 73, e2833-e2834.	5.8	2
22	Letter to the Editor. Clinical Infectious Diseases, 2020, 70, 719.	5.8	0
23	Reported \hat{l}^2 -Lactam and Other Antibiotic Allergies in Solid Organ and Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2020, 71, 1587-1594.	5.8	22
24	A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. Clinical Infectious Diseases, 2020, 71, 2777-2786.	5.8	53
25	Circulating exosomes with lung self-antigens as a biomarker for chronic lung allograft dysfunction: A retrospective analysis. Journal of Heart and Lung Transplantation, 2020, 39, 1210-1219.	0.6	24
26	Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation. Clinical Microbiology Reviews, 2020, 34, .	13.6	45
27	Expedited SARS-CoV-2 screening of donors and recipients supports continued solid organ transplantation. American Journal of Transplantation, 2020, 20, 3106-3112.	4.7	13
28	Use of SARS-CoV-2-infected deceased organ donors: Should we always "just say no?― American Journal of Transplantation, 2020, 20, 1787-1794.	4.7	74
29	Emerging evidence to support not always "just saying no―to SARS-CoV-2 positive donors. American Journal of Transplantation, 2020, 20, 3261-3262.	4.7	20
30	Detection of SARS-CoV-2 by bronchoscopy after negative nasopharyngeal testing: Stay vigilant for COVID-19. Respiratory Medicine Case Reports, 2020, 30, 101120.	0.4	24
31	Current Understanding of Cytomegalovirus Reactivation in Critical Illness. Journal of Infectious Diseases, 2020, 221, S94-S102.	4.0	21
32	Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in highâ€risk donor seropositive/recipient seronegative heart transplant recipients. Transplant Infectious Disease, 2020, 22, e13255.	1.7	9
33	Xanthogranulomatous Pyelonephritis With Direct Extension Into the Liver. American Journal of Medicine, 2020, 133, 1054-1055.	1.5	6
34	Earliest cases of coronavirus disease 2019 (COVIDâ€19) identified in solid organ transplant recipients in the United States. American Journal of Transplantation, 2020, 20, 1885-1890.	4.7	82
35	Presentation of BK polyomavirus–associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. Blood Advances, 2020, 4, 617-628.	5.2	39
36	Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors. JAMA - Journal of the American Medical Association, 2020, 323, 1378.	7.4	103

#	Article	IF	Citations
37	Predictive Value of Respiratory Viral Detection in the Upper Respiratory Tract for Infection of the Lower Respiratory Tract With Hematopoietic Stem Cell Transplantation. Journal of Infectious Diseases, 2019, 221, 379-388.	4.0	22
38	Listing practices and graft utilization of hepatitis C–positive deceased donors in liver and kidney transplant. Surgery, 2019, 166, 102-108.	1.9	9
39	Varicella zoster virus in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13622.	1.6	71
40	Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis. Journal of Infectious Diseases, 2019, 220, 752-760.	4.0	27
41	Hepatitis C NAT status in the UNOS database. American Journal of Transplantation, 2019, 19, 1870.	4.7	1
42	A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients. American Journal of Transplantation, 2019, 19, 2505-2516.	4.7	84
43	Trillions and Trillions: Herpes Simplex Virus–1 Hepatitis in an Immunocompetent Adult. Open Forum Infectious Diseases, 2019, 6, ofz465.	0.9	4
44	Cytomegalovirus immunoglobulin G titers do not predict reactivation risk in immunocompetent hosts. Journal of Medical Virology, 2019, 91, 836-844.	5.0	10
45	Transplant tourism complicated by lifeâ€threatening New Delhi metalloâ€Î²â€lactamaseâ€1 infection. American Journal of Transplantation, 2019, 19, 1224-1228.	4.7	9
46	Prediction of Infection After Solid Organ Transplantation: Is Measuring Cell-Mediated Immunity the Answer?. Clinical Infectious Diseases, 2018, 66, 1398-1399.	5.8	7
47	Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients. Transplantation, 2018, 102, 632-639.	1.0	8
48	NAT testing in recipients of hepatitis C aviremic donor organs. American Journal of Transplantation, 2018, 18, 1030.	4.7	1
49	LB21. Preemptive Therapy (PET) vs. Prophylaxis for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Donor Seropositive/Recipient Seronegative (D+Râ^') Liver Transplant Recipients (LTR): A NIH-Sponsored, Randomized, Controlled, Multicenter Trial. Open Forum Infectious Diseases, 2018, 5, S766-S766.	0.9	5
50	Clinical characteristics and outcomes of lateâ€onset BK virus nephropathy in kidney and kidneyâ€pancreas transplant recipients. Transplant Infectious Disease, 2018, 20, e12928.	1.7	11
51	Donorâ€derived hepatitis C in the era of increasing intravenous drug use: A report of the Disease Transmission Advisory Committee. Clinical Transplantation, 2018, 32, e13370.	1.6	16
52	Willingness to Consider Increased-Risk Donors: A Single-Center Experience in Kidney Transplantation. Annals of Transplantation, 2018, 23, 387-392.	0.9	8
53	A Dark Horse Diagnosis. Journal of Hospital Medicine, 2018, 13, 790-794.	1.4	0
54	Expanding access to transplantation with hepatitis Câ€positive donors: A new perspective on an old issue. Clinical Transplantation, 2017, 31, e12884.	1.6	11

#	Article	IF	Citations
55	Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients. Clinical Infectious Diseases, 2017, 65, 57-63.	5.8	81
56	Variability in assessing for BK viremia: whole blood is not reliable and plasma is not above reproach - a retrospective analysis. Transplant International, 2017, 30, 670-678.	1.6	3
57	Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness. JAMA - Journal of the American Medical Association, 2017, 318, 731.	7.4	91
58	Comparison of self-collected nasal swabs with oral washes for sequential viral load monitoring in lung transplant recipients with respiratory virus infection. Journal of Clinical Virology, 2017, 91, 49-51.	3.1	2
59	ls Kidney Donor Profile Index (KDPI) Valid for Hepatitis C Aviremic Kidneys?. Annals of Transplantation, 2017, 22, 663-664.	0.9	8
60	Changing landscape of hepatitis C virus-positive donors. World Journal of Hepatology, 2017, 9, 905.	2.0	2
61	A Prospective Study Comparing Self-Collected Nasal Swabs to Oral Washes for Monitoring Viral Load Kinetics in Lung Transplant Recipients With Respiratory Virus Infection. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
62	Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation, 2016, 100, 210-216.	1.0	10
63	Respiratory virus infections and chronic lung allograft dysfunction: Assessment of virology determinants. Journal of Heart and Lung Transplantation, 2016, 35, 946-947.	0.6	12
64	Symptomatic Respiratory Virus Infection and Chronic Lung Allograft Dysfunction. Clinical Infectious Diseases, 2016, 62, 313-319.	5.8	92
65	Infection control strategies that successfully controlled an outbreak of Mycobacterium abscessus at a cystic fibrosis center. American Journal of Infection Control, 2016, 44, 154-159.	2.3	21
66	Cytomegalovirus Infection After Solid Organ Transplantation. , 2016, , 441-475.		2
67	Coreactivation of Human Herpesvirus 6 and Cytomegalovirus Is Associated With Worse Clinical Outcome in Critically Ill Adults*. Critical Care Medicine, 2015, 43, 1415-1422.	0.9	39
68	Changing the paradigm of organ utilization from <scp>PHS</scp> increasedâ€risk donors: an opportunity whose time has come?. Clinical Transplantation, 2015, 29, 724-727.	1.6	24
69	Time to Antibiotics in Solid Organ Transplant Recipients With Gram-Negative Rod Bloodstream Infections. Clinical Infectious Diseases, 2015, 60, 1868-1869.	5 . 8	1
70	A patient self-collection method for longitudinal monitoring of respiratory virus infection in solid organ transplant recipients. Journal of Clinical Virology, 2015, 62, 98-102.	3.1	7
71	Infections in Solid-Organ Transplant Recipients. , 2015, , 3440-3452.		18
72	1225Co-Reactivation of Human Herpesvirus 6 (HHV-6) and Cytomegalovirus (CMV) is Associated with Worse Clinical Outcome in Critically III Immunocompetent Adults. Open Forum Infectious Diseases, 2014, 1, S43-S43.	0.9	O

#	Article	IF	Citations
73	Reply to Munoz and Santin. Clinical Infectious Diseases, 2014, 58, 905-906.	5.8	2
74	Rapid Detection of Human Cytomegalovirus UL97 and UL54 Mutations Directly from Patient Samples. Journal of Clinical Microbiology, 2013, 51, 2354-2359.	3.9	18
75	Quantitation of Cytomegalovirus DNA Load in Dried Blood Spots Correlates Well with Plasma Viral Load. Journal of Clinical Microbiology, 2013, 51, 2360-2364.	3.9	12
76	Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients. Transplant International, 2011, 24, 920-931.	1.6	22
77	Update and Review: State-of-the-Art Management of Cytomegalovirus Infection and Disease Following Thoracic Organ Transplantation. Transplantation Proceedings, 2011, 43, S1-S17.	0.6	83
78	Extended Valganciclovir Prophylaxis in D+/ $R\hat{a}^{-}$ Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study. Transplantation, 2010, 90, 1427-1431.	1.0	175
79	Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation. Annals of Internal Medicine, 2010, 152, 761.	3.9	212
80	CMV in critically ill patients: pathogen or bystander?. Reviews in Medical Virology, 2010, 20, 372-379.	8.3	74
81	Programmed Death–1 Expression in Liver Transplant Recipients as a Prognostic Indicator of Cytomegalovirus Disease. Journal of Infectious Diseases, 2008, 197, 25-33.	4.0	63
82	Marked Variability of BK Virus Load Measurement Using Quantitative Real-Time PCR among Commonly Used Assays. Journal of Clinical Microbiology, 2008, 46, 2671-2680.	3.9	138
83	Cytomegalovirus Reactivation in Critically Ill Immunocompetent Patients. JAMA - Journal of the American Medical Association, 2008, 300, 413.	7.4	401
84	Systematic Assessment of Culture Review as a Tool to Assess Errors in the Clinical Microbiology Laboratory. Archives of Pathology and Laboratory Medicine, 2008, 132, 1792-1795.	2.5	3
85	Human Polyomaviruses., 2008, , 1058-1062.		0
86	Incidence and Clinical Features of Ganciclovir- Resistant Cytomegalovirus Disease in Heart Transplant Recipients. Clinical Infectious Diseases, 2007, 45, 439-447.	5.8	96
87	Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral Prophylaxis. Transplantation, 2006, 81, 1645-1652.	1.0	217
88	Functional Comparison and Longitudinal Assessment of Tri-Functional T-Cells Recognizing CMV pp65 and IE-1 Polypeptides in Hematopoietic Stem Cell and Solid Organ Transplant Recipients Blood, 2006, 108, 2936-2936.	1.4	0
89	Polyomavirus-Associated Nephropathy in Renal Transplantation: Interdisciplinary Analyses and Recommendations. Transplantation, 2005, 79, 1277-1286.	1.0	842
90	Polyomavirus Nephropathy in Native Kidneys of Nonâ€Renal Transplant Recipients. American Journal of Transplantation, 2005, 5, 614-620.	4.7	112

#	Article	IF	Citations
91	Cross-Reactivity of T Lymphocytes Recognizing a Human Cytotoxic T-Lymphocyte Epitope within BK and JC Virus VP1 Polypeptides. Journal of Virology, 2005, 79, 11170-11178.	3.4	80
92	Clinical Impact Associated with Corrected Results in Clinical Microbiology Testing. Journal of Clinical Microbiology, 2005, 43, 2188-2193.	3.9	30
93	Invasive Pneumococcal Infections in Adult Lung Transplant Recipients. American Journal of Transplantation, 2004, 4, 1366-1371.	4.7	27
94	Polyomavirus Nephropathy in Pediatric Kidney Transplant Recipients. American Journal of Transplantation, 2004, 4, 2109-2117.	4.7	136
95	BK virus-associated nephropathy in kidney transplant recipients. Reviews in Medical Virology, 2004, 14, 193-205.	8.3	34
96	Late-Onset Cytomegalovirus Disease in Liver Transplant Recipients Despite Antiviral Prophylaxis 1. Transplantation, 2004, 78, 1390-1396.	1.0	141
97	Treatment of Refractory BK Virus-Associated Nephropathy With Cidofovir. American Journal of Transplantation, 2003, 3, 186-191.	4.7	166
98	Statin Use and Bone Mineral Density in Renal Transplant Recipients. American Journal of Transplantation, 2003, 3, 1320-1321.	4.7	53
99	Six Rapid Tests for Direct Detection of Clostridium difficile and Its Toxins in Fecal Samples Compared with the Fibroblast Cytotoxicity Assay. Journal of Clinical Microbiology, 2003, 41, 667-670.	3.9	84
100	High Incidence of Ganciclovirâ€Resistant Cytomegalovirus Infection among Lung Transplant Recipients Receiving Preemptive Therapy. Journal of Infectious Diseases, 2002, 185, 20-27.	4.0	216
101	Ganciclovirâ€Resistant Cytomegalovirus in Organ Transplant Recipients. Clinical Infectious Diseases, 2002, 35, 866-872.	5.8	175
102	Antiviral resistance in cytomegalovirus: An emerging problem in organ transplant recipients. Seminars in Respiratory Infections, 2002, 17, 265-273.	1.3	44
103	Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet, The, 2000, 356, 645-649.	13.7	505
104	Transmission of Histoplasma capsulatumby Organ Transplantation. New England Journal of Medicine, 2000, 343, 1163-1166.	27.0	139
105	Pseudomembranous Colitis Caused by a Toxin A ^{â^'} B ⁺ Strain of <i>Clostridium difficile</i> . Journal of Clinical Microbiology, 2000, 38, 1696-1697.	3.9	104
106	Treatment of Tularemia with Fluoroquinolones: Two Cases and Review. Clinical Infectious Diseases, 1999, 29, 922-924.	5.8	98
107	Outbreak of Stenotrophomonas maltophilia Bacteremia Among Patients Undergoing Bone Marrow Transplantation: Association With Faulty Replacement of Handwashing Soap. Infection Control and Hospital Epidemiology, 1999, 20, 756-758.	1.8	37
108	Detection of Epstein-Barr Virus DNA in Sera from Transplant Recipients with Lymphoproliferative Disorders. Journal of Clinical Microbiology, 1999, 37, 1113-1116.	3.9	109

ARTICLE

IF CITATIONS

Direct Detection of Legionellae in Respiratory Tract Specimens by Using Fluorescence In Situ
Hybridization., 0,, 221-224.